

# **Supporting Information**

**Development of Novel 1,3-Disubstituted-2-Thiohydantoin Analogues with Potent Anti-Inflammatory Activity; *In Vitro* and *In Silico* Assessments**

Salma M. Khirallah <sup>1</sup>, Heba M. M. Ramadan <sup>2</sup>, Ahmed Shawky <sup>3</sup>, Safa H Qahl <sup>4</sup>,  
Roua S. Baty <sup>5</sup>, Nada Alqadri <sup>6</sup>, Amnah Mohammed Alsuhaibani <sup>7</sup>, Mariusz Jaremko <sup>8</sup>,  
Abdul-Hamid Emwas <sup>9</sup>, and Essa M. Saied <sup>10,11,\*</sup>





Figure S1a. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 3 in DMSO-*d*<sub>6</sub>.



**Figure S1b:** The keto-enol tautomer of compound **3**.




Figure S2. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 4 in DMSO-*d*<sub>6</sub>.




Figure S3. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 5 in DMSO-*d*<sub>6</sub>.




Figure S4. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 6 in DMSO-*d*<sub>6</sub>.




Figure S5. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 7 in DMSO-*d*<sub>6</sub>.





Figure S6. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of compound 8 in DMSO-*d*<sub>6</sub>.



**Table S1: *In vitro* cytotoxicity of 1,3 disubstituted-2-thioxoimidazolidin-4-one derivatives against LPS-induced RAW264.7.**


**Compound 3**

log conc.	% viability
3	45.09
2.398	54.99
1.799	67.86
1.204	78.37
0.6	90.78




**Compound 4**

log conc.	% viability
3	43.27
2.39794	51.55
1.79934	63.07
1.20412	72.57
0.6	84.35




**Compound 5**

log conc.	% viability
3	39.26
2.398	47.99
1.799	58.86
1.204	68.82
0.6	80.66




**Compound 6**

log conc.	% viability
3	41.6
2.39794	49.25
1.79934	61.26
1.20412	66.48
0.6	77.99




### Compound 7

log conc.	% viability
3	40.06
2.39794	48.44
1.79934	55.83
1.20412	66.26
0.6	78.9




### Compound 8

log conc.	% viability
3	41.54
2.398	53.67
1.799	63.56
1.204	73.13
0.6	84.83



### CXB

log conc.	% viability
3	41.32
2.398	48.25
1.799	59.79
1.204	70.51
0.6	79.25




**Table S2: Effect of compound 7 on IL-6 and TNF- $\alpha$  expression in RAW264.7 by RT-PCR.**

	LPS-induced raw264.7 cells				
	Sample			Gene Expression	
		conc ug/ml	cells	Fold of change	
				IL6	TNF $\alpha$
1	7	50		0.276	0.314
2	Celecoxib	50		0.353	0.484
3	Positive Control	---		1	1

**Table S3: In vitro effect of compound 7 on Western blot analysis of IL-1 $\beta$  in RAW264.7 cells.**

	Compound			western blotting	
	code	conc ug/ml	cells	IL1B	$\beta$ -actin
				OD	
1	7	10	raw264.7	0.395	
2	7	50		0.341	+
3	PC	---		0.709	+



**Figure S7.** Western plot analysis of the *in vitro* Anti-inflammatory effect of compound **7** against LPS- activated RAW264.7 cell line on IL-1 $\beta$  expression.